Carisma Therapeutics Inc <CARM.OQ> expected to post a loss of 9 cents a share - Earnings Preview
Carisma Therapeutics Inc CARM.OQ CARM.O is expected to show a fall in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
The United States of America-based company is expected to report a 59.2% decrease in revenue to $3.75 million from $9.2 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Carisma Therapeutics Inc is for a loss of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 20.0% in the last three months.
Wall Street's median 12-month price target for Carisma Therapeutics Inc is $1.00, about 68.9% above its last closing price of $0.31
This summary was machine generated August 4 at 12:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
